The implication of lncRNA expression pattern and potential function of lncRNA RP4‐576H24.2 in acute myeloid leukemia

Abstract

Background Recent studies have revealed that long noncoding RNAs (lncRNAs) may hold crucial triggers of the pathogenesis of hematological malignancies, while the studies evaluating the expression pattern of lncRNA in acute myeloid leukemia (AML) are few. Thus, this study aimed to investigate the implication of lncRNA expression pattern in AML development and progression. Methods Bone marrow samples from four AML patients and four controls were subjected to lncRNA sequencing. Then, bone marrow samples from 110 AML patients and 40 controls were proposed to real‐time quantitative polymerase chain reaction (RT‐qPCR) validation for 10 candidate lncRNAs. Clinical data and survival profiles were recorded in AML patients. Furthermore, lncRNA RP4‐576H24.2 expression in AML cell lines and its effect on AML cell proliferation and apoptosis were detected. Results LncRNA expression pattern by sequencing clearly distinguished AML patients from controls, and 630 upregulated and 621 downregulated lncRNAs were identified in AML patients compared to controls, which were mainly enriched in AML oncogene‐related biological process and pathways (such as neutrophil degranulation, leukocyte transendothelial migration, and hematopoietic cell lineage). RT‐qPCR validation observed that six lncRNAs correlated with AML risk, one lncRNA associated with risk stratification, and three lncRNAs correlated with survivals, among which lncRNA RP4‐576H24.2 was the only one correlated with AML susceptibility, risk stratification, and survivals. Further in vitro experiments showed that lncRNA RP4‐576H24.2 was upregulated in AML cell lines compared to normal bone marrow mononuclear cells (BMMCs), and promoted proliferation while inhibited apoptosis in HL‐60 and KG‐1 cells. Conclusions LncRNA expression pattern is closely involved in the development and progression of AML, and several specific lncRNAs exhibit potential to be biomarkers for AML risk and prognosis. Besides, lncRNA RP4‐576H24.2 might be a potential oncogene in AML pathogenesis.

Long noncoding RNAs: A novel insight in the leukemogenesis and drug resistance in acute myeloid leukemia

“…The levels of CCDC26 were reported to be correlated with risk stratification as well as remission. The upregulation of CCDC26 provides the poor outcome of AML patients and is associated with low survival (Zheng et al, 2019). LncRNA PANDAR is another potential prognostic factor in AML that is located at chromosome 6q21.2.…”

“…provides the poor outcome of AML patients and is associated with low survival (Zheng et al, 2019). LncRNA PANDAR is another potential prognostic factor in AML that is located at chromosome 6q21.2.…”

The Regulation of circRNA RNF13/miRNA-1224-5p Axis Promotes the Malignant Evolution in Acute Myeloid Leukemia

“…So far, a variety of cytogenetic and molecular indicators have been widely recognized in clinical practice and become a powerful tool to assist diagnosis, guide treatment, and prognosis stratification. In recent years, a large number of researches focusing on DNA mutation, microRNA, and lncRNA are widely carried out, aiming to find more biological indicators of AML and improve the understanding of the characteristics of leukemia, so as to help monitor minimal residual lesions, improve the ability of early warning, and develop new targeted therapeutic drugs [ 6 – 8 ].…”

Long non‐coding RNA as potential diagnostic markers for acute myeloid leukemia: A systematic review and meta‐analysis

“…Moreover, lncRNA detection is both noninvasive and highly specific, positioning lncRNAs promising as diagnostic indicators, predictive biomarkers, and potential therapeutic targets in cancer. 23 , 24 , 25 …”